BACKGROUND: Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy. OBJECTIVE: In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas. METHODS: Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described. RESULTS/ CONCLUSIONS: Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.
BACKGROUND: Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy. OBJECTIVE: In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas. METHODS: Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described. RESULTS/ CONCLUSIONS: Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.
Authors: Arnold I Freeman; Zichria Zakay-Rones; John M Gomori; Eduard Linetsky; Linda Rasooly; Evgeniya Greenbaum; Shira Rozenman-Yair; Amos Panet; Eugene Libson; Charles S Irving; Eithan Galun; Tali Siegal Journal: Mol Ther Date: 2005-10-28 Impact factor: 11.454
Authors: Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James Journal: Neuro Oncol Date: 2005-04 Impact factor: 12.300
Authors: Rachel M Schowalter; Mark A Wurth; Hector C Aguilar; Benhur Lee; Carole L Moncman; Richard O McCann; Rebecca Ellis Dutch Journal: Virology Date: 2006-02-28 Impact factor: 3.616
Authors: Takafumi Nakamura; Kah-Whye Peng; Mary Harvey; Suzanne Greiner; Ian A J Lorimer; Charles D James; Stephen J Russell Journal: Nat Biotechnol Date: 2005-01-30 Impact factor: 54.908
Authors: M J Driesse; A J Vincent; P A Sillevis Smitt; J M Kros; P M Hoogerbrugge; C J Avezaat; D Valerio; A Bout Journal: Gene Ther Date: 1998-08 Impact factor: 5.250
Authors: B Mrkic; J Pavlovic; T Rülicke; P Volpe; C J Buchholz; D Hourcade; J P Atkinson; A Aguzzi; R Cattaneo Journal: J Virol Date: 1998-09 Impact factor: 5.103
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun Journal: CA Cancer J Clin Date: 2006 Mar-Apr Impact factor: 508.702
Authors: N Shinoura; S C Heffelfinger; M Miller; O I Shamraj; N H Miura; J J Larson; N DeTribolet; R E Warnick; J J Tew; A G Menon Journal: Cancer Lett Date: 1994-11-11 Impact factor: 8.679
Authors: Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant Journal: Neurosurg Focus Date: 2015-03 Impact factor: 4.047
Authors: Adam W Studebaker; Brian Hutzen; Christopher R Pierson; Terri A Shaffer; Corey Raffel; Eric M Jackson Journal: Neuro Oncol Date: 2015-04-02 Impact factor: 12.300